

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Atty Dkt. 2801-36

C# M#

FANTO et al

Group Art Unit: 1621

Serial No. 09/533,381

Examiner: Barts

Filed: March 26, 2001

Date: December 19, 2001

Title: 2-AMINOTETRALINES AND PHARMACEUTICAL COMPOSITIONS FOR THE  
PREVENTION AND THERAPEUTIC TREATMENT OF INFLAMMATORY AND/OR  
AUTOIMMUNE PATHOLOGIES

Assistant Commissioner for Patents  
Washington, DC 20231



Sir:

**RESPONSE/AMENDMENT/LETTER**

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

**Fees are attached as calculated below:**

Total effective claims after amendment 9 minus highest number  
previously paid for 20 (at least 20) = 0 x \$ 18.00 \$ 0.00

Independent claims after amendment 9 minus highest number  
previously paid for 9 (at least 3) = 0 x \$ 84.00 \$ 0.00

If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper) \$ 0.00

Petition is hereby made to extend the current due date so as to cover the filing date of this  
paper and attachment(s) (\$110.00/1 month; \$400.00/2 months; \$920.00/3 months) \$ 0.00

Terminal disclaimer enclosed, add \$ 110.00 \$ 0.00

☐ First/second submission after Final Rejection pursuant to 37 C.F.R. 1.129(a) (\$740.00) \$ 0.00

☐ Please enter the previously unentered, filed

☐ Submission attached

RECEIVED  
DEC 21 2001  
TECH CENTER 1600/2900

Subtotal \$ 0.00

If "small entity," then enter half (1/2) of subtotal and subtract -\$ 0.00

☐ Applicant claims "small entity" status. ☐ Statement filed herewith

Rule 56 Information Disclosure Statement Filing Fee (\$180.00) \$ 0.00

Assignment Recording Fee (\$40.00) \$ 0.00

Other: 0.00

**TOTAL FEE ENCLOSED \$ 0.00**


The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8<sup>th</sup> Floor  
Arlington, Virginia 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100  
ARC:lsj

NIXON &amp; VANDERHYE P.C.

By Atty: Arthur R. Crawford, Reg. No. 25,327

Signature: 



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of

FANTO et al

Serial No. 09/533,381

Filed: March 26, 2001

Atty. Ref.: 2801-36

Group: 1621

Examiner: Barts

For: 2-AMINOTETRALINES AND PHARMACEUTICAL COMPOSITIONS FOR THE  
PREVENTION AND THERAPEUTIC TREATMENT OF INFLAMMATORY  
AND/OR AUTOIMMUNE PATHOLOGIES

\* \* \* \* \*

December 19, 2001

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**RESPONSE**

**RECEIVED**  
**DEC 21 2001**  
**TECH CENTER 1600/2900**

Responsive to the Official Action dated December 7, 2001, Paper No. 4, and requirement for restriction presented in it, applicants elect the subject matter of Group II, namely, claims 9, 12 and 15 drawn to a method of preventing or treating septic shock. Specific embodiments of the invention are disclosed in the data given on pages 40-47 of the specification.

Responsive to item 4 of the Official Action, the elected single disclosed species is (R,S)-2-amino-6-fluoro-7-methyltetraline hydrochloride (ST 1275) which is disclosed in the specification at page 6, line 12, and otherwise identified throughout the specification and data as ST 1275.

This response is made with traverse. The compounds disclosed in the present application are effective in counteracting the aetiopathogenetic role of inflammatory cytokines (see page 1, first paragraph). Inflammatory cytokines are responsible for septic

shock and inflammatory and/or autoimmune pathologies (see page 1, last paragraph to page 2, first paragraph).

Examination on the merits is awaited taking into account the Information Disclosure Statement filed March 26, 2001.

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By: \_\_\_\_\_



Arthur R. Crawford  
Reg. No. 25,327

ARC:lsp  
1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100